Skip to main content
Equibles
FATE logo

FATE · Fate Therapeutics Inc · Webcasts, Transcripts & Audio

Track FATE — free

Use FATE with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research FATE.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.32 +0.02 (+0.87%) At close · Oct 2
Rebalance outlook locked
Market Cap
$281.58M
Shares
119.82M
Volume · Oct 2 658.02K Avg daily vol (3M) 1.92M

Fate Therapeutics Inc Webcasts

Earnings calls, investor updates, investor days and conferences for Fate Therapeutics Inc (FATE), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲94% $5.46M −$28.07M '20 Q2 20-08-05 ▲211.2% $7.56M −$58.68M '20 Q3 20-11-05 ▲467.3% $15.90M −$53.11M '20 Q4 21-02-24 ▲343% $11.14M −$45.09M '21 Q1 21-05-05 ▲145.4% $13.41M −$55.13M '21 Q2 21-08-04 ▲88.2% $14.22M −$43.31M '21 Q3 21-11-04 ▲7.4% $17.07M −$68.62M '21 Q4 22-02-28 ▲65.3% $18.41M −$65.69M '22 Q1 22-05-04 ▲38.3% $18.55M −$76.11M '22 Q2 22-08-03 ▲5.3% $14.98M −$83.56M '22 Q3 22-11-03 ▲159.9% $44.36M −$56.36M '22 Q4 23-02-28 ▲220.3% $58.98M −$18.88M '23 Q1 23-05-03 ▼95% $933,000 −$52.76M '23 Q2 23-08-08 ▼87% $1.94M −$45.17M '23 Q3 23-11-08 ▼96.2% $1.68M −$44.12M '23 Q4 24-02-26 LATEST ▼96.7% $1.93M −$48.00M '24 Q1 24-05-09
Earnings call
FY24 · Q1
2024-05-09
Fate Therapeutics Inc (FATE) Q1 2024 Earnings Call Transcript
Confident tone FT819 clinical data in autoimmunity FT522 CAR NK cell program Pipeline focus and strategic prioritization
Revenue
$1.93M
▼ 96.7% YoY
Diluted EPS
$-0.47
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-26
Fate Therapeutics Inc (FATE) Q4 2023 Earnings Call Transcript
Confident tone FT819 CD19 CAR T-cell program Autoimmunity expansion FT522 NK cell program with ADR technology
Revenue
$1.68M*
▼ 96.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Fate Therapeutics Inc (FATE) Q3 2023 Earnings Call Transcript
Revenue
$1.94M
▼ 87% YoY
Diluted EPS
$-0.46
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Fate Therapeutics Inc (FATE) Q2 2023 Earnings Call Transcript
Revenue
$933,000
▼ 95% YoY
Diluted EPS
$-0.54
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-03
Fate Therapeutics Inc (FATE) Q1 2023 Earnings Call Transcript
Revenue
$58.98M
▲ 220.3% YoY
Diluted EPS
$-0.19
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-28
Fate Therapeutics Inc (FATE) Q4 2022 Earnings Call Transcript
Revenue
$44.36M*
▲ 159.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Fate Therapeutics Inc (FATE) Q3 2022 Earnings Call Transcript
Revenue
$14.98M
▲ 5.3% YoY
Diluted EPS
$-0.86
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-03
Fate Therapeutics Inc (FATE) Q2 2022 Earnings Call Transcript
Revenue
$18.55M
▲ 38.3% YoY
Diluted EPS
$-0.79
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
Fate Therapeutics Inc (FATE) Q1 2022 Earnings Call Transcript
Revenue
$18.41M
▲ 65.3% YoY
Diluted EPS
$-0.68
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-28
Fate Therapeutics Inc (FATE) Q4 2021 Earnings Call Transcript
Revenue
$17.07M*
▲ 7.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Fate Therapeutics Inc (FATE) Q3 2021 Earnings Call Transcript
Revenue
$14.22M
▲ 88.2% YoY
Diluted EPS
$-0.45
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-04
Fate Therapeutics Inc (FATE) Q2 2021 Earnings Call Transcript
Revenue
$13.41M
▲ 145.4% YoY
Diluted EPS
$-0.58
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-05
Fate Therapeutics Inc (FATE) Q1 2021 Earnings Call Transcript
Revenue
$11.14M
▲ 343% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-02-24
Fate Therapeutics Inc (FATE) Q4 2020 Earnings Call Transcript
Revenue
$15.90M*
▲ 467.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Fate Therapeutics Inc (FATE) Q3 2020 Earnings Call Transcript
Revenue
$7.56M
▲ 211.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-05
Fate Therapeutics Inc (FATE) Q2 2020 Earnings Call Transcript
Revenue
$5.46M
▲ 94% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-11
Fate Therapeutics Inc (FATE) Q1 2020 Earnings Call Transcript
Revenue
$2.52M
▼ 4.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-02
Fate Therapeutics Inc (FATE) Q4 2019 Earnings Call
Revenue
$2.80M
▲ 68.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–18 of 18 webcasts
Key facts CIK 1434316 CUSIP 31189P102 13F (30d) 3 filings 3 filers Visit website Investor relations